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A B S T R A C T
We report 7 cases of strongyloidiasis that had occurred from 2016 through 2017 in a tertiary hospital of southern
China. Three of the 7 patients (age 66–77) with farming exposure many years ago developed symptomatic
infection while receiving immunosuppressant for underlying medical conditions. The majority of them were
treated with albendazole due to unavailability of ivermectin in mainland China. One of the 7 patients, with
underlying IgG4 sclerosing cholangitis and secondary biliary cirrhosis was on immunosuppressives and devel-
oped severe pancytopenia 15 days after albendazole treatment. He ultimately died of polymicrobial sepsis. This
was the second fatal case being reported in the literature as a consequence of albendazole-induced myelosup-
pression. We have undertaken a review of the literature regarding the use of albendazole for strongyloidiasis and
its adverse eﬀect with a focus on myelosuppression as a rare but potentially serious event.
Introduction
Strongyloides stercoralis infection remains endemic in developing
countries in tropics asnd subtropics. The ability to complete lifecycle
inside human body enables the helminth to persist for years after ac-
quisition. Immunosuppression later in life suppresses the T-cell re-
sponse in controlling the worm burden, and can result in hyperinfection
and even dissemination. Patient may develop severe pneumonia and
even meningitis at the most severe end of spectrum. Although prompt
treatment with antihelminthics like albendazole and ivermectin can be
life-saving, the side eﬀects of them could be fatal in turn. We report a
case series involving 7 patients with strongyloidiasis, in which one of
them died due to myelosuppression from albendazole.
Case series
We prospectively followed up and collected data on all laboratory
conﬁrmed cases of Strongyloides stercoralis infections at The University
of Hong Kong-Shenzhen Hospital in mainland China between July 2016
and November 2017.
Seven cases of strongyloidiasis were encountered over the period of
time. Details of the patients has been summarized in Table 1. Four of
the seven patients were male. The age ranged from 49 to 83 years-old.
Six of them had worked as farmers in paddy ﬁelds in the past. The two
patients that presented with intestinal strongyloidiasis were not on any
immunosuppressants, and both improved after 7 days of albendazole.
The remaining ﬁve patients suﬀered from either hyperinfection or
disseminated disease. Four of the ﬁve patients (80%) were taking cor-
ticosteroids for underlying autoimmune diseases. Three of those four
patients with either hyperinfection or disseminated strongyloidiasis,
were treated with albendazole alone achieving parasitological cure.
Patient 5 with underlying IgG4 sclerosing cholangitis and secondary
biliary cirrhosis on prednisolone 40mg daily presented as hyperinfec-
tion. His sputum showed S. stercoralis that produced crawling tracks on
agar. This patient developed severe pancytopenia after 15 days of al-
bendazole, complicated by polymicrobial neutropenic sepsis. He de-
veloped bacteremia due to ESBL producing Klebsiella pneumoniae, as
well as methicillin-resistant Staphylococcus aureus (MRSA) pneumonia
and Cunninghamella pulmonary mucormycosis, ﬁnally succumbed with
multiple cavitating lung lesions (Fig. 1). Although there was no evi-
dence of strongyloidiasis from the respiratory specimen at the time of
demise, parasitological clearance could not be declared as treatment
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was not completed and there were no documented negative specimen
2–4 weeks after albendazole. Bone marrow examination showed ex-
treme hypocellularity and trilineage hypoplasia (Fig. 2). This is the
second fatal case reported in the literature as a result of albendazole-
induced myelosuppression.
Discussion
About 55–100 million people are infected by S. stercoralis world-
wide each year [1]. The prevalence of S. stercoralis infection in China
had been reported as 0.12% [2]. There was a regional variation with a
higher prevalence noted in the southern and southwestern provinces
such as Yunnan (11.7%) [3] and a lower prevalence in eastern part of
China such as Shandong (1.29%) [4]; and in the more arid Western
China (0.04%) [5]. Six of our 7 patients had past history of farming and
had come from Guangdong province of South China. It was most likely
that they had acquired the S. stercoralis infection from the paddy ﬁeld
by exposing the bare skin of their legs and feet to the soil. The two of
patients that developed intestinal symptoms only were not on any im-
munosuppressants whereas 4 of the remaining 5 patients with hyper-
infection or disseminated disease were.
Both ivermectin and albendazole have been used for intestinal
strongyloidiasis without hyperinfection or dissemination. However,
ivermectin has not been available in China for a number of years as the
sole manufacturer for ivermectin in China has discontinued its pro-
duction. A review article was published in 2016 comparing the eﬃcacy
of albendazle and ivermectinin the treatment of uncomplicated stron-
gyloidiasis (i.e. no evidence of hyperinfection or dissemination) [6]. It
was found that a single dose or two doses of ivermectin (each dose
200 μg/kg) was more eﬃcacious in achieving a parasitological cure in
each of the 4 published trials compared with 3–7 days of albendazole
(daily dose of 400–800mg). The pooled risk ratio is 1.79 (95% con-
ﬁdence interval 1.55-2.08). The rate of parasitological cure for iver-
mectin was 82.7%–95%; whereas it was 37.5–63.3% for albendazole
[6]. Historically, thiabendazole had been another drug of choice for
treating uncomplicated strongyloidiasis. Even though it had been
shown to demonstrate similar eﬃcacy in parasitological cure compared
with ivermectin (risk ratio 1.07, 95% conﬁdence interval 0.96–1.20), it
was not favored due to more adverse events [6]. As expected, our two
patients with uncomplicated strongyloidiasis were successfully treated
with 7 days of oral albendazole.
To date, no trials have been reported that compared the eﬃcacy
Fig. 1. High-resolution computerized tomography scan of patient 5 with cavitating lung lesions due to albendazole-induced pancytopenia over left upper lobe with
surrounding halo sign.
Fig. 2. Bone marrow biopsy of patient 5 showing hypocellular marrow with trilineage hypoplasia.
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between ivermectin and albendazole in the treatment of complicated
strongyloidiasis (i.e. hyperinfection or disseminated diseases due to S.
stercoralis). The existing experience and recommendations have been
based on case reports. Buonfrate et al. summarized the clinical features,
treatment and outcome of 133 cases of complicated strongyloidiasis
receiving single agent for treatment between 1991 and 2011 [7]. The
mortality of patients receiving ivermectin only was 47% (18 out of 38
patients), whereas mortality of patients receiving albendazole only was
73% (25 out of 34 patients). No further statistical analysis was per-
formed in this systematic review. In our series, 4 out of the 5 patients
with hyperinfection or disseminated strongyloidiasis were treated with
albendazole (patients 3–6), with or without ivermectin. Patient 4
achieved parasitological cure after 21 days of albendazole given at
400mg twice daily. Patient 3 had symptomatic recurrence despite
parasitological cure, required additional of ivermectin. Patient 6 also
achieved parasitological cure after 2 days of albendazole. Patient 5 was
treated with a course of albendazole but died without any doc-
umentation of parasitological clearance, as it requires negative sputum
and stool exams performing 2–4 weeks after treatment. Therefore, al-
bendazole achieved parasitological cure in 3 out of 4 patients while the
remaining patient without documented clearance eventually suc-
cumbed.
Albendazole belongs to the benzimidazole class of drugs and is used
to treat a wide range of parasitic diseases. It is generally well tolerated
with low incidences of gastrointestinal discomfort. Rarely, albendazole
is associated with more severe side eﬀects such as leukopenia (0.044%),
anemia (0.004%), and raised liver enzymes (0.035%) [8]. One of our
patients (patient 5) was noted to have pancytopenia 15 days after al-
bendazole treatment. He went on and developed Klebsiella pneumoniae
bacteremia, MRSA pneumonia, and pulmonary mucormycosis due to
Cunninghamella spp. and died of multiorgan failure soon afterwards. On
review of the literature, there was one other fatal case of albendazole-
induced pancytopenia, being reported by Opatrny et al. and which was
similar to our patient 5 [9]. In Opatrny’s report, the patient was started
on albendazole for hydatid cyst disease and developed pancytopenia 16
days after the treatment. It was complicated by Klebsiella pneumoniae
bacteremia, and the patient died of esophageal variceal bleeding due to
severe thrombocytopenia. In 2014, there were 2 cases of bilineage cy-
topenia reported separately [10,11], both following a month of alben-
dazole treatment for hydatid cyst disease. The case reported by Fredj
[10] developed leukopenia and thrombocytopenia, while the other case
reported by Açıkgöz [11] developed thrombocytopenia and anemia. It
is noteworthy that severe bone marrow suppression in these cases had
developed after a prolonged duration of albendazole of over 10 days,
used to treat extra-intestinal Angiostrongylus infection and hydatid cyst
disease respectively. Albendazole kills parasites by inhibiting tubulin
polymerization, resulting in the loss of cytoplasmic microtubules [12].
It is postulated that the inhibition of tubulin might impair the cell
turnover of actively dividing cells of human e.g. hematopoietic cells,
thus leading to bone marrow suppression after prolonged exposure. The
eﬀect might be exacerbated in patients with preexisting liver failure as
albendazole is metabolized in liver to less potent metabolites such as
albendazole sulfoxide [9]. Our patient is the second fatal case being
reported in the literature as a result of albendazole-induced myelosu-
pression. We recommend careful monitoring of full blood count in cases
where albendazole is being used, especially in prolonged course (> 10
days), or where there is pre-existing liver dysfunction.
In view of the potential fatal outcome of complicated strongyloi-
diasis and treatment limitation, screening of patient at risk might pro-
vide an important step in preventing its development. Risk factors for
hyperinfection and disseminated strongyloidiasis include the use of
immunosuppressive drugs including corticosteroids, the presence of
human T-lymphotropic virus-1 (HTLV-1) infection, recipients of solid
organ or hematological stem cell transplant, patients with hematolo-
gical malignancy, hypogammaglobulinemia, uremia, severe malnutri-
tion, or diabetes mellitus [13]. It may be prudent to screen patients for
intestinal carriage of Strongyloides before starting immunosuppression
where there are also a past history of farming, residence or travel to
endemic area. The sensitivity of single stool examination is only 75.9%
for intestinal carriage of S. stercoralis, but increases to 92% with 3 stool
specimens [14]. However, the negative predictive value varies with
local disease prevalence. In a low prevalence setting, the use of ser-
ological testing is preferable. In the past, immunoﬂuoresence antibody
testing against Strongyloides had been used predominantly. More re-
cently, the use of enzyme-linked immunosorbent assay (ELISA) and
luciferase immunoprecipitation system (LIPS) had increased the sensi-
tivity up to 97%, and the negative predictive value is nearly 100% in
low prevalence setting [15]. Stool molecular testing is only used in a
few reference laboratories and the sensitivity is unclear at this stage.
Southern China has relatively high prevalence of Strongyloides stercor-
alis. Hence, we recommend screening with multiple stool microscopy
examination and a peripheral blood examination for eosinophil count
before commencement of immunosuppressive therapy.
Conclusion
In summary, we have reported 7 cases of strongyloidiasis and its
course of treatment that had occurred in an endemic part of China.
Immunosuppression appeared to be an important risk factor for the
development of complicated strongyloidiasis. Albendazole induced
myelosuppression is a rare but serious concern and may lead to death
through neutropenic sepsis. Hence, the use of albendazole should be
accompanied by careful and close monitoring of full blood count
especially during prolonged treatment.
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